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Background and Purpose: Cerebral ischemia is a common, morbid condition accompanied 
by cognitive decline. Recent reports on the vascular health beneﬁ  ts of ﬂ  avanol-containing foods 
signify a promising approach to the treatment of cerebral ischemia. Our study was designed 
to investigate the effects of ﬂ  avanol-rich cocoa (FRC) consumption on cerebral blood ﬂ  ow in 
older healthy volunteers.
Methods: We used transcranial Doppler (TCD) ultrasound to measure mean blood ﬂ  ow velocity 
(MFV) in the middle cerebral artery (MCA) in thirty-four healthy elderly volunteers (72 ± 6 
years) in response to the regular intake of FRC or ﬂ  avanol-poor cocoa (FPC).
Results: In response to two weeks of FRC intake, MFV increased by 8% ± 4% at one week 
(p = 0.01) and 10% ± 4% (p = 0.04) at two weeks. In response to one week of cocoa, signiﬁ  -
cantly more subjects in the FRC as compared with the FPC group had an increase in their MFV 
(p  0.05).
Conclusions: In summary, we show that dietary intake of FRC is associated with a signiﬁ  cant 
increase in cerebral blood ﬂ  ow velocity in the MCA as measured by TCD. Our data suggest a 
promising role for regular cocoa ﬂ  avanol’s consumption in the treatment of cerebrovascular 
ischemic syndromes, including dementias and stroke.
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Introduction
Endothelial function is an important determinant of cardiovascular performance 
(Stefanadis et al 2000; London et al 2001; Perticone et al 2001). Endothelium-derived 
factors, most notably nitric oxide (NO), play a major role in the control of vascular 
biology, not only in the peripheral but also in the cerebral circulation. NO deﬁ  ciency 
has been associated with the development of atherosclerosis and increased cardio-
vascular risk (for reviews: Busse and Fleming 1996; Gewaltig and Kojda 2002), and 
also with delayed vasospasm in subarachnoid hemorrhage (Pluta 2006) and cerebral 
hypoperfusion in ischemic syndromes (Zhang and Iadecola 1994; Iadecola et al 1997; 
Kielstein and Zoccali 2005). Since the discovery of nitric oxide synthase (NOS) in the 
brain and cerebral arteries (Iadecola 1993; Iadecola et al 1993), evidence is mounting 
to secure NO as a critical regulator of brain perfusion.
A number of epidemiological studies have shown that regular consumption of 
foods and beverages rich in ﬂ  avanols is associated with a decreased risk of cardio- and 
cerebrovascular mortality (Knekt et al 1996; Commenges 2000; Galli 2002; Youdim 
2002). In the context of human nutrition, ﬂ  avanols occur in noteworthy amounts 
in speciﬁ  c foods and beverages, including some teas and red wines (Renaud and 
de Lorgeril 1992) and, especially, cocoa (Hammerstone et al 2000). Replenishing 
endothelium-derived NO reserves may be involved in the vasoprotective effects 
of ﬂ  avanols. In vitro data show that cocoa protects the vascular endothelium by 
improving NO availability (Karim et al 2000; Heiss et al 2003). Our group has Neuropsychiatric Disease and Treatment 2008:4(2) 434
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recently shown that dietary intake of ﬂ  avanol-rich cocoa 
(FRC) was associated with peripheral vasodilation in 
healthy human subjects via activation of the NO system, 
providing a plausible mechanism for the vasoprotective 
effects of ﬂ  avanol-rich foods (Fisher et al 2003). The work 
of others supports this concept (Heiss et al 2003). Moreover, 
we have also shown that FRC enhanced several measures 
of endothelial function to a greater degree among older 
healthy subjects, who have impaired endothelial function 
as compared to the younger healthy subjects (Fisher and 
Hollenberg 2006). Data from a recent pilot study using 
functional magnetic resonance imaging (fMRI) showed an 
increase in the blood oxygenation level-dependent (BOLD) 
signal intensity in response to a cognitive task following 
the regular consumption of moderate doses (5 days of 
150 mg) of cocoa ﬂ  avanols in 16 healthy young subjects 
(Francis et al 2006). However, to this date, there have not 
been any direct studies on the effects of FRC on cerebral 
blood ﬂ  ow in humans.
Our study was designed to investigate the acute and short-
term effects of FRC consumption on cerebral blood ﬂ  ow 
in older healthy volunteers. We used transcranial Doppler 
(TCD) ultrasound to: (1) assess cerebral blood ﬂ  ow responses 
following one week of dietary intervention with either FRC 
or a ﬂ  avanol-poor cocoa (FPC) control; and to (2) charac-
terize the acute and short-term cerebral blood ﬂ  ow response 
following 2 weeks of dietary FRC intake.
Methods
Subjects
Thirty-four healthy people aged 59–83 years (mean 72 ± 5.7 
years) volunteered to participate in this study. Thirteen of 
the 34 subjects participated in a 2 week study exploring the 
acute and steady state cerebral blood ﬂ  ow responses to dietary 
consumption of FRC. Twenty-one of the 34 subjects partici-
pated in a randomized, double-masked, placebo-controlled, 
parallel-arm study of the cerebral blood ﬂ  ow response to one 
week of daily FRC versus ﬂ  avanol-poor cocoa (FPC) intake. 
Subjects were recruited from the Harvard Cooperative Pro-
gram on Aging subject registry. All subjects were carefully 
screened with a medical history, physical examination, and 
electrocardiogram to exclude any acute or chronic medical 
conditions. Subjects were nonsmokers with normal blood 
pressure and without diabetes; they refrained from alcohol, 
caffeine and all chocolate intake for at least 12 hours. See 
Table 1. The study was approved by the Partners Health-
care institutional review board, and followed institutional 
guidelines.
Experimental protocol
Instrumentation
Subjects reported to the General Clinical Research 
Center at the Brigham and Women’s Hospital in the post-
absorptive state, 2 hours after their last meal. Subjects 
were instrumented for heart rate (HR electrocardiogram) 
and beat-to-beat arterial pressure monitoring (ABP, 
Finapres, Ohmeda Monitoring Systems, Englewood, CO) 
as previously described (Sorond et al 2005). End-tidal CO2 
was measured from nasal prongs, using a Vacumed CO2 
Analyzer (Ventura, CA).
TCD ultrasonography (MultiDop X4, DWL-Transcranial 
Doppler Systems Inc., Sterling, VA) was used to measure 
changes in middle cerebral artery (MCA) blood ﬂ  ow veloc-
ity (MFV) at rest and in response to changes in end-tidal 
CO2 (cerebral vasoreactivity, VR) before and after cocoa 
consumption. The same technician performed all the studies 
and the depths of insonation were recorded so they could 
be duplicated in the follow-up study. The MCA signal was 
identiﬁ  ed according to the criteria of Aaslid and colleagues 
(1982) and recorded at a depth of 50 to 60 mm. A Mueller-
Moll probe ﬁ  xation device was used to stabilize the Doppler 
probe for the duration of the study. The envelope of the 
velocity waveform, derived from a fast-Fourier analysis 
of the Doppler frequency signal, was digitized at 500 Hz, 
displayed simultaneously with the ABP, ECG, and end-tidal 
CO2 signals, and stored for later off-line analysis.
Cerebral vasoreactivity(VR)
Changes in MCA MFV were measured during alterations in 
end-tidal CO2 (Maeda et al 1994) to determine the effects 
of dietary intake of a FRC and FPC beverage on cerebral 
VR to CO2. In this technique cerebral MFVs in the MCA 
were measured continuously while subjects inspired a gas 
mixture of 5% CO2, 21% O2, and balance nitrogen for 2 
minutes and then mildly hyperventilated to an end-tidal CO2 
of approximately 25 mmHg for 2 minutes. To determine 
cerebrovascular reactivity using this technique, percent 
Table 1 Baseline subject characteristics
  Time course of  Flavanol-rich vs 
 MFV  response  ﬂ  avanol-poor cocoa
N 13  21
M:F ratio  5:8  1.1:1
Age, y  72.5 (4)  72.2 (6)
Mean arterial pressure  83.9 (13)  74.3 (24)
MCA baseline MFV, cm/s  47.0 (19)  54.2 (10)
Notes: All values are mean (SD).
Abbreviations: MCA, middle cerebral artery; MFV, mean blood ﬂ  ow velocity.Neuropsychiatric Disease and Treatment 2008:4(2) 435
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change in MCA blood ﬂ  ow velocities was plotted against end 
tidal CO2 in response to room air, breathing 5% CO2 and mild 
hyperventilation. Cerebral VR was measured as the slope of 
this relationship and expressed as percent change in cerebral 
blood ﬂ  ow per mmHg change in end-tidal CO2. In addition, 
in order to reﬂ  ect changes in ABP, we have also calculated 
VR as the slope of the relationship between cerebrovascular 
conductance (CVC = MFV/ABP) and end-tidal CO2. This is 
referred to as VRcvc.
Time course of cerebral blood ﬂ  ow response
Thirteen of the subjects (8 female and 5 male, 72.5 ± 4 
years) were enrolled in the time course study to investigate 
the effect of acute and short-term intake of FRC on cerebral 
blood ﬂ  ow velocity in the MCA. The FRC (Cocoapro™, 
Mars, Incorporated) beverage used in this study was a dairy-
based cocoa drink formulated to deliver 900 mg of cocoa 
ﬂ  avanols daily, in divided doses. The drink packet was a 
dry blend that was reconstituted with water just prior to 
consumption. The compositional details of this drink (and 
the FPC drink) can be found in Table 2. On the ﬁ  rst day 
of the study, MCA MFV measurements were taken prior 
to the consumption of the beverage and the again at 2, 4, 
6 and 8 hours after ingestion of one serving of FRC (450 
mg ﬂ  avanols). Baseline study was done before breakfast 
(fasting) and before the ﬁ  rst dose of the beverage. Lunch 
was served between readings at 4 and 6 hours. After this 
baseline study, volunteers were provided with the appropri-
ate number of drink packets and asked to consume 2 packets 
(900 mg ﬂ  avanols daily) of the beverage daily for two weeks. 
Participants returned at 7 and 14 days for repeat MCA MFV 
studies at baseline and at 2, 4, 6, and 8 hours after one serving 
(450 mg cocoa ﬂ  avanols) of FRC.
Flavanol-rich versus ﬂ  avanol-poor cocoa
Twenty-one subjects (10 females and 11 males, 72.2 ± 
6 years) were randomized in accordance with a double-
masked, parallel-arm placebo-controlled study, designed 
to compare the effect of one week of dietary intake of FRC 
versus FPC on MCA blood ﬂ  ow velocity. The FRC and 
FPC drinks were formulated so that they were matched for 
calories, macronutrients, micronutrients, and alkaloids and 
were indistinguishable by taste and overall appearance (see 
Table 2). To ensure that the identity of the drinks remained 
unknown to the investigators and study participants, the 
drink packets were provided in individually wrapped and 
coded packets.
After assessing the resting cerebral blood ﬂ  ow veloc-
ity and cerebral vasoreactivity in the MCA territory, each 
subject was randomized to a group and asked to consume 
2 packets of either the FRC (900 mg ﬂ  avanols per day) or 
FPC (36 mg ﬂ  avanols per day) for one week. Study partici-
pants returned for a follow-up visit at the same time of the 
day as the baseline study to minimize the effect of diurnal 
variations in CBF.
TCD data processing
All data were displayed and digitized in real time at 500 
Hz with commercially available data acquisition software 
(Windaq, Dataq Instruments). MFV and BP waveforms were 
re-sampled at 1 Hz using a MATLAB program. Beat-to-beat 
R-R interval, ABP (expressed as mean arterial pressure) and 
MFV (expressed as mean ﬂ  ow velocity) were determined 
from the R wave of the ECG and the maximum and minimum 
of the arterial pressure or MFV waveforms.
Beat-to-beat values for ABP and ABP were averaged 
across each trial for each individual. Cerebrovascular resis-
tance (CVR) was calculated as the ratio of ABP to MFV.
Statistical analysis
Absolute values in MCA, MFV, and CVR, as well as ABP 
were compared using repeated measures ANOVA. For the 
FRC versus FPC comparison, changes in MCA, VR, MFV, 
CVR, and ABP were compared between FRC and FPC using 
a Student’s t-test. Chi-squared analysis was used to compare 
FRC versus FPC responders. Signiﬁ  cance was set at p  0.05. 
Data are expressed as mean ± SE.
Table 2 Nutritional content of the study beverages
 Flavanol-rich  Flavanol-poor
  cocoa (FRC)  cocoa (FPC)
Cocoa ﬂ  avanols, mg  451.1  18.2
Calories 118.1  117.2
Total fat, g  1.4  1.5
Cholesterol, mg  4.4  4.9
Total carbohydrates, g  17.1  16.5
Dietary ﬁ  ber, g  3.0  3.9
Sugars, g  9.4  9.2
Protein, g  9.4  9.4
Caffeine, mg  18.3  21.2
Theobromine, mg  336.5  327.4
Sodium, mg  105.1  155.0
Potassium, mg  530.1  644.8
Calcium, mg  243.7  241.2
Iron, mg  1.9  2.9
Phosphorous, mg  280.2  265.4
Magnesium, mg  85.9  78.4
Zinc, mg  1.6  1.6
Copper, mg  0.4  0.4
Manganese, mg  0.6  0.6Neuropsychiatric Disease and Treatment 2008:4(2) 436
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Results
Time course of cerebral blood 
ﬂ  ow response
Two weeks of FRC intake had a consistent and statistically 
signiﬁ  cant (n = 13; p = 0.04) effect on peak cerebral blood 
ﬂ  ow responses. The peak and steady state cerebral blood ﬂ  ow 
response prior to and following one and two weeks of daily 
FRC consumption is summarized in Figure 1. At baseline, 
one serving of FRC drink (450 mg cocoa ﬂ  avanols) resulted 
in an initial decrease in resting MCA MFV at 2 and 4 hours 
post consumption, which gradually returned to baseline at 6 
and 8 hours. After one week of daily FRC consumption, a 
single serving of the FRC drink was again associated with 
an initial decrease in MFV at 2 and 4 hours, which subse-
quently increased to 2% ± 2% (p = 0.14) at 6 hours and 8% 
± 4% (p = 0.01) at 8 hours after ingestion. After two weeks 
of FRC ingestion, the cerebral blood ﬂ  ow response continued 
to increase, with a smaller initial decrease at 2 and 4 hours, 
followed by a small increase at 6 hours and a signiﬁ  cant 
increase at 8 hours (10% ± 4%, p = 0.04) post FRC. Overall, 
MAP and CVR did not change signiﬁ  cantly in response to 
two weeks of FRC intake.
Flavanol-rich versus ﬂ  avanol-poor cocoa
Cerebrovascular hemodynamic responses following either 
one week of FRC or FPC consumption are summarized in 
Table 3. One week of either FRC or FPC ingestion did not 
have a signiﬁ  cant effect on blood pressure, CVR, or cerebral 
vasoreactivity.
Despite variable individual blood ﬂ  ow response, 6/11 
subjects had at least a 10% increase in MFV following the 
consumption of the FRC drink. In sharp contrast, only 1 in 10 
volunteers consuming the FPC drink demonstrated a 10% or 
greater change in MFV (p  0.05 by chi-squared analysis). 
Although the FRC group had a larger percent increase in 
their MFV (54% ± 30% on FRC and 16% ± 2 % on FPC), 
because of larger variability in the responses, these group 
differences did not reach statistical signiﬁ  cance.
Discussion
To our knowledge, this is the ﬁ  rst study to directly investigate 
the effect of both acute and short-term FRC consumption on 
cerebral blood ﬂ  ow. We show that two weeks of regular FRC 
intake, providing 900 mg of cocoa ﬂ  avanols daily, resulted in 
a signiﬁ  cant increase in peak cerebral blood ﬂ  ow response in 
the MCA. In most subjects, there was an initial decrease of 
cerebral blood ﬂ  ow during the ﬁ  rst 2–4 hours after intake of 
a single serving of FRC. This response was attenuated over 
time and is most likely related to the caffeine content of cocoa 
(Cameron et al 1990; Lunt et al 2004; Haase et al 2005). The 
mechanisms underlying ﬂ  avanol-mediated increased cerebral 
blood ﬂ  ow responses are unknown. Given that the cerebral 
blood ﬂ  ow changes were not associated with signiﬁ  cant 
changes in blood pressure, other regulatory mechanisms, such 
as metabolic factors may be involved. The enhanced cerebral 
blood ﬂ  ow response to FRC over two weeks is suggestive of 
an activated biochemical pathway where subsequent stimuli 
result in a potentiated response. Based on early in vitro data 
that showed NOS activation by ﬂ  avanols (Karim et al 2000; 
Schroeter et al 2006) and our own work, which showed 
that FRC induced NO-dependent peripheral vasodilation 
in healthy humans (Fisher et al 2003), we propose that the 
cerebrovascular effects of FRC consumption are also NO- 
dependent. Studies using speciﬁ  c NOS inhibitors, such as 
N(G)-nitro-L- arginine methyl ester (L-NAME), will help 
to better deﬁ  ne this pathway in the future.
Cocoa is known to be rich in theobromine, a meth-
ylxanthine, and to contain much lower amounts of its 
structurally close relative caffeine. Our ﬂ  avanol-rich cocoa 
drink contained about 30 mg caffeine and about 600 mg 
theobromine; the FRC drink contained nearly the same 
levels of both these alkaloids per serving. Scant data are 
available regarding the biologic effects of theobromine, 
although generally it is considered a weaker stimulant and 
a milder diuretic than caffeine (Schroeder 1951; Dorfman 
and Jarvik 1970). The cerebral hemodynamic effects of 
theobromine have not been reported in humans. In rats caf-
feine resulted in greater reductions in CBF as compared with 
theobromine (Grome and Stefanovich 1986). On the other 
hand, the acute cerebrovascular effects of caffeine are better 
understood. Caffeine has consistently been shown to reduce 
cerebral blood ﬂ  ow signiﬁ  cantly, averaging 23%–30% 
reduction with acute dosing (Cameron et al 1990; Field 
et al 2003; Liu et al 2004). It is likely, therefore, that any 
increase in cerebral blood ﬂ  ow measured acutely follow-
ing FRC consumption must emerge upon a background of 
vasoconstriction induced by its methylxanthine ingredients. 
The early fall in CBF seen in the time course studies likely 
represents the effects of the methylxanthines, which are 
then overcome.
Interventions that improve cerebral blood ﬂ  ow may have 
therapeutic implications for dementia and stroke, and also 
for orthostatic hypotension. The promise of decreasing the 
decline in cognitive function seen with dementia syndromes 
through maintenance of cerebral blood ﬂ  ow is real. Data 
from a recent pilot study demonstrate that acute ingestion of Neuropsychiatric Disease and Treatment 2008:4(2) 437
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Figure 1 The cerebral blood ﬂ  ow (MCA MFV), blood pressure (MAP), and CVR response to FRC ingestions over 8 hours. Baseline denotes the response to the ﬁ  rst dose. 
The same subjects were restudied at day 7 and 14 of the FRC-based dietary intervention. Note the sustained increase in the acute cerebral blood ﬂ  ow in response to FRC intake.
Notes: *and # denote points which show statistically signiﬁ  cant changes from baseline.
Abbreviations: MCA, middle cerebral artery; MFV, mean blood ﬂ  ow velocity; MAP, mean arterial pressure; CVR, cerebrovascular resistance; FRC, ﬂ  avanol-rich cocoa.
FRC could increase the cerebral blood ﬂ  ow to gray matter 
in young healthy volunteers (Francis et al 2006), supporting 
the promising role of cocoa ﬂ  avanols for the treatment of 
dementias and strokes. There is compelling evidence from 
animal studies to show that reduced cerebral blood ﬂ  ow 
plays an initiating role in triggering cognitive dysfunction 
(Farkas et al 2002) and that improving cerebral blood ﬂ  ow 
can improve cognitive behavior (Farkas et al 2002; Basso Neuropsychiatric Disease and Treatment 2008:4(2) 438
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et al 2005). There is a larger body of literature showing 
cerebral hypoperfusion is associated with impaired cognition 
(Ballard et al 1998; Puisieux et al 2001; Goldstein et al 2002; 
Ohtani et al 2003; Verghese et al 2003). We show here that 
the regular consumption of FRC signiﬁ  cantly augments the 
peak cerebral blood ﬂ  ow response. The next step is to deﬁ  ne 
the effects of this augmented peak blood ﬂ  ow response on 
ischemic syndromes as well as on cognitive performance, 
and to determine if it is necessary to achieve steady-state 
blood ﬂ  ow augmentation in order to improve cognitive and 
motor function.
Cerebral blood ﬂ  ow response to one week of daily FRC 
versus daily FPC intake demonstrated a favorable response 
to the FRC drink. Signiﬁ  cantly more individuals responded 
to FRC by increasing their cerebral blood ﬂ  ow. However, 
a statistically signiﬁ  cant difference was not achieved for 
the group steady state cerebral blood ﬂ  ow response. Know-
ing that FPC maintains 40% of the effect of the FPC on 
peripheral vascular responsiveness (Fisher et al 2003), and 
that our group MFV response of 16% to FPC was due to the 
individual response of one outlier, our results are consistent 
with our previous reports of the peripheral vascular response 
following ﬂ  avanol-rich cocoa consumption.
Cognitive impairment due to cerebrovascular disease 
is a rapidly growing public health challenge. Recent 
epidemiological studies indicate that the total prevalence of 
vascular cognitive impairment (VCI), with or without dementia, 
could be as high as 3 million in the United States (Feldman 
et al 2003; Rockwood et al 2003), a number approaching that 
of Alzheimer’s disease (AD). Despite the enormous health 
and ﬁ  nancial costs associated with this cognitive syndrome 
(Fitzpatrick et al 2005; Sicras et al 2005), available treatments 
for VCI are limited to primary and secondary prevention of 
cerebrovascular disease. Recent reports on the vascular health 
beneﬁ  ts of ﬂ  avanol-containing foods, added to our pilot data 
reported in this paper, signify a promising approach to the 
treatment of this cognitive syndrome.
In summary, our results reinforce and extend previously 
published pilot data in healthy young women (Francis et al 2006), 
and suggest that FRC intake directly increases cerebral blood 
ﬂ  ow in healthy elderly subjects. With this information, we can 
proceed to determine the effect of FRC consumption on cerebral 
ischemic syndromes including stroke, vasospasm, and vascular 
cognitive impairment.
Study limitations
We did not have a control for our two-week study subset 
of subjects. The ideal control for FRC would be a cocoa 
drink with equal amounts of methylxanthines, macronu-
trients, electrolytes, and calories, and devoid of ﬂ  avanols. 
The technological and ﬁ  nancial burdens to creating such 
a control are high; although no such control is currently 
available, we have made signiﬁ  cant progress in designing 
this product for future studies. The FPC that was used in 
our one-week study contained some ﬂ  avanols; this may well 
explain the partial peripheral and cerebrovascular responses 
compared with FRC. Moreover, we  did not impose signiﬁ  -
cant dietary restrictions on our subjects beyond avoidance 
of cocoa and caffeine-containing products, so the baseline 
ﬂ  avanol intake of our subjects may have been quite varied. 
Background ﬂ  avanol intake may be a factor that contributes 
to the magnitude of an individual’s response, and should be 
evaluated in future work.
In addition, there a number of issues that can lead to 
enhanced variability in cerebral blood ﬂ  ow measurements 
using the TCD. The most important technical issue is the 
angle of insonation from one study to the other. In our time 
course study, by using a headband, which secured the TCD 
probe in one position through the course of the day, changes 
in angle of insonation between different measurements 
were prevented. However, in our study of FRC vs. FPC, the 
measurements were made two weeks apart. Although we 
recorded from the same depth and used the same technician 
for both studies, it is not possible to be sure that the angle 
was not slightly different. There is also the issue of time of 
day variations in cerebral blood ﬂ  ow velocity, which have 
an approximately 24 hour rhythm under constant conditions, 
suggesting regulation by a circadian oscillator.
Table 3 Cerebrovascular hemodynamics in response to one week of cocoa consumption
 Baseline           One  week       
  MAP MFV CVR  VR  VRcvc  MAP MFV CVR  VR  VRcvc
FRC  88 (4)  45 (7)  2.6 (0.6)  1.3 (0.3)  0.062 (0.1)  83 (4)  53 (4)  1.7 (0.2)  1.4 (0.3)  0.006 (0.0)
FPC  80 (4)  49 (5)  1.9 (0.3)  1.6 (0.4)  0.004 (0.0)  78 (4)  50 (5)  2.1 (0.5)  1.4 (0.2)  0.001 (0.0)
Notes: All values are mean (SE).
Abbreviations: MAP, mean arterial pressure; MCA, middle cerebral artery; MFV, mean blood ﬂ  ow velocity in the MCA; CVR, cerebrovascular resistance in the MCA (MAP/
MFV);   VR, cerebral vasoreactivity in the MCA (slope of MFV and CO2);  VRcvc, cerebral vasoreactivity in the MCA (slope of CVC and CO2); CVC, cerebrovascular conductance 
in the MCA (MFV/MAP); FRC, ﬂ  avanol-rich cocoa; FPC, ﬂ  avanol-poor cocoa.Neuropsychiatric Disease and Treatment 2008:4(2) 439
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It is also important to note that transcranial Doppler 
ultrasound cannot provide an absolute measurement of cere-
bral blood ﬂ  ow , and BFV is assumed to represent blood ﬂ  ow 
through the MCA because it is assumed that the diameter of 
the MCA remains constant during manoeuvres that change 
cerebral blood ﬂ  ow. Using the thigh-cuff test, Newell and 
colleagues (1994) have shown that the absolute ﬂ  ow in the 
carotid artery showed a relative change and time course 
similar to velocity in the MCA. More recently, Serrador and 
colleagues (2000) reported that during CO2 manipulation or 
lower body negative pressure up to 40 mmHg suction there 
were no changes detected in the diameter of MCA. Studies 
using a variety of techniques (133Xe, SPECT, MRI) have 
conﬁ  rmed that relative changes in CBF velocity are repre-
sentative of changes in CBF (Bishop et al 1986; Sorteberg 
et al 1989; Dahl et al 1992; Vorstrup et al 1992; Larsen et al 
1994, 1995; Sugimori et al 1995; Ulrich et al 1995; Clark 
et al 1996). Despite the lack of evidence about changes in 
the MCA diameter, this possibility cannot be eliminated and 
has to be acknowledged.
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